Bank of Jackson Hole Trust Buys New Shares in Stryker Co. (NYSE:SYK)

Bank of Jackson Hole Trust purchased a new position in Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,792 shares of the medical technology company's stock, valued at approximately $645,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SYK. Chicago Capital LLC boosted its holdings in Stryker by 3.1% in the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after buying an additional 5,841 shares during the period. Zhang Financial LLC lifted its position in shares of Stryker by 55.0% in the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock valued at $41,366,000 after acquiring an additional 40,784 shares in the last quarter. Appleton Partners Inc. MA boosted its stake in shares of Stryker by 5.0% in the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock worth $10,521,000 after acquiring an additional 1,400 shares during the period. Dale Q Rice Investment Management Ltd bought a new stake in Stryker during the 4th quarter valued at approximately $587,000. Finally, Berkshire Bank lifted its holdings in Stryker by 13.8% in the 4th quarter. Berkshire Bank now owns 8,489 shares of the medical technology company's stock worth $3,056,000 after purchasing an additional 1,030 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Down 1.0 %

NYSE SYK traded down $3.82 during trading on Friday, hitting $382.59. The stock had a trading volume of 1,268,413 shares, compared to its average volume of 1,388,856. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a 50 day simple moving average of $377.92 and a 200 day simple moving average of $368.21. The stock has a market capitalization of $145.99 billion, a price-to-earnings ratio of 49.30, a P/E/G ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the company posted $3.46 earnings per share. Sell-side analysts predict that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio is presently 43.30%.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Robert W. Baird increased their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. lifted their price target on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. UBS Group increased their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Tuesday. Finally, The Goldman Sachs Group increased their price target on Stryker from $384.00 to $427.00 and gave the company a "neutral" rating in a research note on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.